Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028.

Diabetes 52

Diabetes Drug Development 52

European Pharmaceutical Review

DECEMBER 30, 2023

There is also a high unmet need in the CNS space, and there have been a number positive results with respect to drug development; as a result, we expect this to be a therapeutic area with dealmaking potential,” Baral continues. We expect the growth gap to increase to $120 billion across the top 25 biopharma companies by 2028.

Drug Development 105

Drug Development 105

Express Pharma

SEPTEMBER 24, 2023

CYB-003, a small-molecule drug that is indicated for major depressive disorder, is expected to launch in the US in December 2027 and is forecast to generate $1.4 SPL-026 is also a small-molecule drug. It is expected to launch in the US in 2027 and in the EU in 2028 and generate $0.9 billion in sales in 2029.

Drug Development 52

Drug Development Compounding 52

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. Billion by 2028. Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity.

Drug Development 52

Drug Development 52

pharmaphorum

AUGUST 2, 2022

Merck is no stranger to ADC technology; over the past few years the company has steadily added ADC drug candidates to its pipeline, including through a $2.75 billion deal for VelosBio , a research agreement with Starpharma , and a previous drug development deal with Seagen , under its former name Seattle Genetics.

Compounding 98

Compounding Drug Development 98

STAT

SEPTEMBER 12, 2024

The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. Continue to STAT+ to read the full story…

Drug Development 333

Drug Development Vaccines 333

Pharmaceutical Technology

AUGUST 24, 2022

CAGR between 2020 and 2028. Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. Each sample they give is precious, as they all provide a wealth of biological data that contributes to therapy development.

Method Validation 52

Method Validation Immunity Immunization Drug Development 52

Putting Patients First Blog

OCTOBER 31, 2024

3430 , the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act, would reduce the amount of cost-sharing a patient might be responsible for in Medicare Part D drugs beginning in 2028. For instance, Section 203 of S.3430 The NHC is calling for Congress to pass this provision in the lame duck session.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Drug Development 52

Pharmaceutical Technology

AUGUST 12, 2022

By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. Notable Phase II drugs include Allogene Therapuetics’s ALLO-501A, Autolus Therapeutics’s obecabtagene autoleucel, CASI Pharmaceuticals’s CNCT-19, Precision Biosciences’s PBCAR-0191, and Mustang Bio’s MB-106.

Immunity 52

Immunity Immunization Chemotherapy Compounding 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

European Pharmaceutical Review

FEBRUARY 7, 2023

of the MDR and Article 110.4 of the IVDR for medical devices and in vitro diagnostic medical devices (IVDs).

Packaging 117

Packaging Drug Development 117

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Vaccines 105

Vaccines Drug Development 105

European Pharmaceutical Review

NOVEMBER 1, 2023

He is an experienced biotech and technology industry executive with international experience in drug development, data science, sales and marketing, and business management. Bacterial vaccines in clinical and preclinical development 2021 [Internet]. Bacterial vaccines in clinical and preclinical development 2021 [Internet].

Vaccines 115

Vaccines Immunity Immunization Drug Development 115

European Pharmaceutical Review

MARCH 12, 2025

MSD shared that a further $8 billion of US capital investment is anticipated by 2028. Enhancing drug development capacity In October 2024, MSD acquired full global rights to the next generation CD3xCD19 bispecific antibody to treat B-cell associated diseases, from the biotech Curon Biopharmaceutical.

Research Laboratories 52

Research Laboratories Vaccines Drug Development 52

Pharmaceutical Technology

APRIL 27, 2023

Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022. billion by 2028. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6

Vaccines 52

Vaccines Drug Development Documentation Communication 52

STAT

NOVEMBER 14, 2024

“At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms and multiple modalities,” said Dean Li, the president of Merck Research Laboratories, in a statement.

Research Laboratories 348

Research Laboratories Drug Development 348

STAT

JUNE 4, 2025

billion in revenue last year, lapses in 2028. At issue before the PTO are certain enzymes called Mdase that Halozyme developed to enable the administration of drugs by injection. Patent protection for the treatment, which is currently administered intravenously and generated $29.5

Drug Development 235

Drug Development 235

European Pharmaceutical Review

JANUARY 23, 2025

For instance, patent expiries are set to wipe out $300 billion in revenues by 2028. FDA Issues First Recommendations On AI For Drug Development. As part of this transaction, a small molecule tyrosine kinase inhibitor (TKI) candidate will be advanced as a treatment for gastrointestinal stromal tumours (GIST). cited 2025Jan].

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Drug Development 59